You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
NameCalcium Acetate
Accession NumberDB00258  (APRD00839)
TypeSmall Molecule
DescriptionThe chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]
Acetate OF lime
Brown acetate of lime
calcium ethanoate
calcium(II) acetate
Gray acetate of lime
Lime acetate
Lime pyrolignite
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetatecapsule667 mg/1oralSandoz Inc2012-03-14Not applicableUs
Calcium Acetatecapsule667 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Calcium Acetatecapsule667 mg/1oralSandoz Inc2012-03-14Not applicableUs
Phoslocapsule667 mg/1oralPhysicians Total Care, Inc.2010-03-01Not applicableUs
Phoslocapsule667 mg/1oralFresenius Medical Care North America2001-04-02Not applicableUs
Phoslocapsule667 mg/1oralCardinal Health2001-04-02Not applicableUs
Phoslo Tabletstablet667 mgoralFresenius Medical Care North America2006-02-222013-07-29Canada
Phoslyrasolution667 mg/5mLoralFresenius Medical Care North America2011-04-15Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetatetablet667 mg/1oralCamber Pharmaceuticals, Inc.2014-02-03Not applicableUs
Calcium Acetatecapsule667 mg/1oralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Calcium Acetatecapsule667 mg/1oralMajor Pharmaceuticals2014-10-08Not applicableUs
Calcium Acetatecapsule667 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Calcium Acetatecapsule667 mg/1oralClinical Solutions Wholesale2012-03-14Not applicableUs
Calcium Acetatecapsule667 mg/1oralHeritage Pharmaceuticals Inc.2015-07-07Not applicableUs
Calcium Acetatetablet667 mg/1oralZydus Pharmaceuticals USA Inc.2012-02-23Not applicableUs
Calcium Acetatetablet667 mg/1oralSafecor Health, LLC2014-08-15Not applicableUs
Calcium Acetatecapsule667 mg/1oralLUPIN LIMITED2015-09-09Not applicableUs
Calcium Acetatetablet667 mg/1oralPaddock Laboratories, LLC2011-09-13Not applicableUs
Calcium Acetatecapsule667 mg/1oralAmneal Pharmaceuticals of New York, LLC2014-10-08Not applicableUs
Calcium Acetatecapsule667 mg/1oralAtlantic Biologicals Corps2014-02-03Not applicableUs
Calcium Acetatecapsule667 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Calcium Acetatecapsule667 mg/1oralNostrum Laboratories, Inc.2015-10-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralMc Kesson Contract Packaging2013-04-09Not applicableUs
Calcium Acetatecapsule667 mg/1oralREMEDYREPACK INC.2010-11-112016-10-13Us
Calcium Acetatecapsule667 mg/1oralGolden State Medical Supply, Inc.2015-12-22Not applicableUs
Calcium Acetatecapsule667 mg/1oralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-09-01Not applicableUs
Calcium Acetatecapsule667 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-02-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralAmerican Health Packaging2012-08-27Not applicableUs
Calcium Acetatecapsule667 mg/1oralCardinal Health2008-02-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralLupin Pharmaceuticals, Inc.2015-09-09Not applicableUs
Calcium Acetatecapsule667 mg/1oralCamber Pharmaceuticals, Inc.2014-02-03Not applicableUs
Calcium Acetatecapsule667 mg/1oralExelan Pharmaceuticals, Inc.2014-04-14Not applicableUs
Calcium Acetatecapsule667 mg/1oralAv Pak2015-11-16Not applicableUs
Calcium Acetatecapsule667 mg/1oralWest Ward Pharmaceuticals Corp.2008-02-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralAtlantic Biologicals Corps2008-02-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralZydus Pharmaceuticals USA Inc.2015-07-07Not applicableUs
Calcium Acetatecapsule667 mg/1oralCipla Usa Inc.,2016-07-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralCardinal Health2013-07-26Not applicableUs
Calcium Acetatecapsule667 mg/1oralAv Kare, Inc.2015-04-09Not applicableUs
Eliphostablet667 mg/1oralKAISER FOUNDATION HOSPITALS2011-08-24Not applicableUs
Eliphostablet667 mg/1oralHawthorn Pharmaceutical, Inc.2009-02-01Not applicableUs
Eliphostablet667 mg/1oralCarilion Materials Management2009-02-01Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetate Tab 667mgtablet667 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1993-12-312002-07-31Canada
Unapproved/Other Products Not Available
International Brands
TeltozanNot Available
Brand mixtures
Aluminum Acetate AstringentTagi Pharma Incorporated
AstringentTAGI Pharma Inc.
Hyperlyte (multi-electrolyte Concentrate)B. Braun Medical Inc
LypholytePharmaceutical Partners Of Canada Inc
Lypholyte Multi-electrolyte Conc InjLyphomed, Division Of Fujisawa Canada Inc.
NutrilyteAmerican Regent, Inc.
Zo Medical Zo Post Procedure Recovery SystemZO Skin Health, Inc.
Calcium acetate monohydrate
ThumbNot applicableDBSALT001536
CAS number62-54-4
WeightAverage: 158.166
Monoisotopic: 157.989199835
Chemical FormulaC4H6CaO4
calcium diacetate
IndicationCalcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
Structured Indications
PharmacodynamicsPatients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Mechanism of actionCalcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.
TargetKindPharmacological actionActionsOrganismUniProt ID
PhosphateSmall moleculeyes
Humannot applicabledetails
Related Articles
Absorption40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationCalcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
Half lifeNot Available
ClearanceNot Available
ToxicityOral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Drug InteractionsNot Available
Food InteractionsNot Available
Synthesis Reference

Alan B. Gancy, “Process of making calcium acetate deicing agents and product.” U.S. Patent US4444672, issued November, 1946.

General ReferencesNot Available
External Links
ATC CodesV03AE04V03AE07
AHFS Codes
  • 40:18.19
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (25.6 KB)
MSDSDownload (72.9 KB)
Predicted ADMET features
Human Intestinal Absorption+0.705
Blood Brain Barrier+0.9601
Caco-2 permeable-0.5258
P-glycoprotein substrateNon-substrate0.8366
P-glycoprotein inhibitor INon-inhibitor0.9806
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9609
CYP450 2C9 substrateNon-substrate0.8335
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateNon-substrate0.7384
CYP450 1A2 substrateNon-inhibitor0.9381
CYP450 2C9 inhibitorNon-inhibitor0.9273
CYP450 2D6 inhibitorNon-inhibitor0.9462
CYP450 2C19 inhibitorNon-inhibitor0.9608
CYP450 3A4 inhibitorNon-inhibitor0.9627
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.985
Ames testNon AMES toxic0.9042
CarcinogenicityCarcinogens 0.5617
BiodegradationReady biodegradable0.9734
Rat acute toxicity1.8756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9812
hERG inhibition (predictor II)Non-inhibitor0.9888
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
  • Roxane laboratories inc
  • Fresenius medical care north america
  • Cypress pharmaceutical inc
Dosage forms
Powder, for solutiontopical
Capsuleoral667 mg/1
Tabletoral667 mg
Tabletoral667 mg/1
Injection, solution, concentrateintravenous
Solutionoral667 mg/5mL
Unit descriptionCostUnit
PhosLo 667 mg capsule1.05USD capsule
Phoslo 667 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6576665 No2001-04-032021-04-03Us
US6875445 No2001-07-302021-07-30Us
US8591938 No2010-02-232030-02-23Us
US8592480 No2007-07-202027-07-20Us
US9089528 No2007-07-202027-07-20Us
Experimental Properties
melting point> 160 °CNot Available
Predicted Properties
Water Solubility147.0 mg/mLALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Mass Spec (NIST)Not Available
SpectraNot Available
DescriptionThis compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acid derivatives
Direct ParentAcetate salts
Alternative Parents
  • Acetate salt
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External Descriptors


Small molecule
Pharmacological action
  1. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5. [PubMed:2811066 ]
  2. Nolan CR, Qunibi WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. [PubMed:12815333 ]
  3. Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl. 2005 Jun;(95):S13-20. [PubMed:15882308 ]
  4. Nolan CR: Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl. 2005 Jul;(96):S7-14. [PubMed:15954948 ]
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 26, 2016 02:38